Biovie Inc (BIVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.12M
Last updated: Nov 17, 2026 at 11:02 AM ET
Biovie Inc (BIVI) Competitors
The companies most similar to Biovie are Vyome Holdings (HIND), VistaGen Therapeutics (VTGN) and Dare Bioscience (DARE). By market cap, Biovie ranks 7th of the 13 companies on this page; Vyne Therapeutics (VYNE) is the largest at $19.07M.
Peer Comparison
BIVI's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Biovie (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| VistaGen Therapeutics Inc (VTGN) | $8.01M | N/A | 3.4x | 0.0% | N/A | -46.5% | 0.00% |
| Dare Bioscience Inc (DARE) | $12.93M | N/A | 6.4x | 0.0% | N/A | 499.6% | 0.00% |
| Biocardia Inc (BCDA) | $12.58M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Vyne Therapeutics Inc (VYNE) | $19.07M | N/A | N/A | 0.0% | N/A | -57.4% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Longeveron LLC (LGVN) | $8.40M | N/A | 5.9x | 0.0% | N/A | -9.2% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Passage Bio Inc (PASG) | $13.68M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Peer median | $11.83M | N/A | 6.4x | 0.0% | -351.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Biovie, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| VistaGen Therapeutics Inc (VTGN) | VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential... | VTGN competitors |
| Dare Bioscience Inc (DARE) | Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. | DARE competitors |
| Biocardia Inc (BCDA) | BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. | BCDA competitors |
| Vyne Therapeutics Inc (VYNE) | VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. | |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| Longeveron LLC (LGVN) | Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. | LGVN competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Passage Bio Inc (PASG) | Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. | PASG competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
Frequently Asked Questions About BIVI
Who are Biovie's main competitors?
The companies most similar to Biovie include Vyome Holdings (HIND), VistaGen Therapeutics (VTGN), Dare Bioscience (DARE), Biocardia (BCDA) and Vyne Therapeutics (VYNE), listed from the closest match.
Who is Biovie's biggest competitor?
Vyne Therapeutics (VYNE) is the largest of the similar companies at $19.07M; Vyome Holdings (HIND) is the closest match by business profile, size, sector and industry.
How does BIVI stock compare with its competitors?
BIVI's net margin is 0.0% against a peer median of 0.0%.
Which of Biovie's competitors pays a higher dividend?
Biovie pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Biovie bigger than its competitors?
No. Biovie is 7th by market cap among the 13 companies on this page; the largest is Vyne Therapeutics (VYNE) at $19.07M.
BIVI pages: Overview, Earnings, Forecast, Financials, Competitors